Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

United States

Research Interests

Explore related searches

Articles (20)

Collaborators (10)

Marjorie Zauderer

Section Chief, Hematology & Medical Oncology

New York Medical College

UNITED STATES

Elad Sharon

Associate Professor

Harvard University

UNITED STATES

Fengmin Zhao

Biostatistician

Dana-Farber Cancer Institute

UNITED STATES

Karen Reckamp

Cedars-Sinai Medical Center

UNITED STATES

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES

Nicholas Mitsiades

University of California, Davis

UNITED STATES

Kevin Kalinsky

Emory University

UNITED STATES

Heather H. Cheng

University of Washington

UNITED STATES

S. Percy Ivy

Associate Chief

National Cancer Institute

UNITED STATES

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lisa McShane

Research Interests

Explore related searches

Articles (20)

Collaborators (10)

Marjorie Zauderer

Elad Sharon

Fengmin Zhao

Karen Reckamp

Robert Gray

Nicholas Mitsiades

Kevin Kalinsky

Heather H. Cheng

S. Percy Ivy

Mohamed Gouda

Make your next move.

Lisa McShane

Research Interests

Explore related searches

Articles (20)

ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K –Mutated Tumor

Phase II Study of Vismodegib in Patients With SMO- or PTCH1 -Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T

PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Evaluating clinical utility of comprehensive genomic profiling—challenges and opportunities

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors

Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

Collaborators (10)

Marjorie Zauderer

Elad Sharon

Fengmin Zhao

Karen Reckamp

Robert Gray

Nicholas Mitsiades

Kevin Kalinsky

Heather H. Cheng

S. Percy Ivy

Mohamed Gouda

Make your next move.